Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Person Details: Rohit Loomba

Superfund Research Program

Rohit Loomba

University of California-San Diego
9500 Gilman Drive, BRF-II/4A18
MC 0063
La Jolla, California 92093-0063
Phone: 858-534-2624
Email: roloomba@health.ucsd.edu

Projects

Publications

2022

  • Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA, Kisseleva T. 2022. Metabolic injury of hepatocytes promotes progression of NAFLD and AALD. Semin Liver Dis 42(3):233-249. doi:10.1055/s-0042-1755316 PMID:36001995
  • Danis N, Weeks SR, Kim A, Baghdadi A, Ghadimi M, Kamel IR, Saberi B, Woreta T, Garonzik-Wang J, Philosophe B, Gurakar A, Loomba R. 2022. Noninvasive risk stratification for nonalcoholic fatty liver disease among living liver donor candidates: A proposed algorithm. Liver Transpl 28(4):670-677. doi:10.1002/lt.26365 PMID:34753223
  • Huang D, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez S, Gupta H, Sirlin CB, Marks RM, Loomba R. 2022. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. Aliment Pharmacol Ther 55(7):820-827. doi:10.1111/apt.16844 PMID:35229334
  • Huang DQ, Singal AG, Kono Y, Tan DJ, El-Serag HB, Loomba R. 2022. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 34(7):969-977. doi:10.1016/j.cmet.2022.05.003 PMID:35793659
  • Liu Y, Meric G, Havulinna AS, Teo SM, Aberg F, Ruuskanen MO, Sanders JG, Zhu Q, Tripathi A, Verspoor K, Cheng S, Jain M, Jousilahti P, Vazquez-Baeza Y, Loomba R, Lahti L, Niiranen TJ, Salomaa VV, Knight R, Inouye M. 2022. Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting. Cell Metab 34(5):719-730. doi:10.1016/j.cmet.2022.03.002 PMID:35354069 PMCID:PMC9097589
  • Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta LM, Brozynska M, Zhu Q, Tripathi A, Vazquez-Baeza Y, Loomba R, Cheng S, Jain M, Niiranen TJ, Lahti L, Knight R, Salomaa VV, Inouye M, Meric G. 2022. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat Genet 54:PMID:35115689
  • Rowe IA, Wong VW, Loomba R. 2022. Treatment candidacy for pharmacologic therapies for NASH. Clin Gastroenterol Hepatol 20:P1209-1217. doi:10.1016/j.cgh.2021.03.005 PMID:33711479 PMCID:PMC8908435
  • Sharpton S, Oh TG, Madamba E, Wang C, Yu RT, Atkins AR, Huan T, Downes M, Evans RM, Loomba R. 2022. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. Aliment Pharmacol Ther doi:10.1111/apt.17236 PMID:36164267
  • Sinakos E, Liava C, Loomba R. 2022. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. Ann Gastroenterol 35(3):213-225. doi:10.20524/aog.2022.0704 PMID:35599922 PMCID:PMC9062842
  • Tamaki N, Ajmera VH, Loomba R. 2022. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 18:doi:10.1038/s41574-021-00584-0 PMID:34815553 PMCID:PMC9012520
  • Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N. 2022. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 20:1171-1173. doi:10.1016/j.cgh.2021.07.021 PMID:34280550 PMCID:PMC8761224
  • Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB and Loomba R. 2022. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 71:983-990. doi:10.1136/gutjnl-2021-324264 PMID:33883248 PMCID:PMC8594562
  • Tapper EB, Ufere NN, Huang DQ, Loomba R. 2022. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 55(9):doi:10.1111/apt.16831 PMID:35235219

2021

  • Ajmera VH, Cachay ER, Ramers CB, Bassirian S, Singh S, Bettencourt R, Richards L, Hamilton G, Middleton MS, Fowler K, Sirlin C, Loomba R. 2021. Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard. Clin Infect Dis 72(12):doi:10.1093/cid/ciaa429 PMID:32975278 PMCID:PMC8204791
  • Ajmera VH, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. 2021. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther 54(1):doi:10.1111/apt.16392 PMID:33975381 (ahead of print)
  • Ajmera VH, Loomba R. 2021. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 50:doi:10.1016/j.molmet.2021.101167 PMID:33460786 PMCID:PMC8324681
  • Ajmera VH, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Sriram K, Insel PA, Collier S, Richards L, Loomba R. 2021. MIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19. Contemp Clin Trials 103:doi:10.1016/j.cct.2021.106330 PMID:33631357 PMCID:PMC7899027
  • Byra M, Han A, Boehringer AS, Zhang YN, O'Brien WD, Erdman JW, Loomba R, Sirlin C, Andre MP. 2021. Liver fat assessment in multiview sonography using transfer learning with convolutional neural networks. J Ultrasound Med 41(1):doi:10.1002/jum.15693 PMID:33749862 (ahead of print)
  • Cariou B, Byrne CD, Loomba R, Sanyal AJ. 2021. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 23:1069-1083. doi:10.1111/dom.14322 PMID:33464677 PMCID:PMC8248154
  • Caussy C, Aubin A, Loomba R. 2021. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep 12:15. doi:10.1007/s11892-021-01383-7 PMID:33742318
  • Dhar D, Loomba R. 2021. Emerging metabolic and transcriptomic signature of PNPLA3-Associated NASH. Hepatology 73:PMID:33544416
  • Haas ME, Friedman SN, Wang M, Emdin CA, Ajmera VH, Simon TG, Homburger JR, Guo X, Budoff M, Corey K, Zhou AY, Philippakis A, Ellinor PT, Loomba R, Batra P, Khera AV, Pirruccello JP. 2021. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 1(3):doi:10.1016/j.xgen.2021.100066 PMID:34957434 PMCID:PMC8699145
  • Hagstrom H, Adams LA, Allen AM, Byrne CD, Chang Y, Gronbaek H, Ismail M, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Aberg F. 2021. Administrative coding in electronic health care record-based research of NAFLD: An expert panel consensus statement. Hepatology 74:474-482. doi:10.1002/hep.31726 PMID:33486773 PMCID:PMC8515502
  • Huang DQ, El-Serag HB, Loomba R. 2021. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223-238. doi:10.1038/s41575-020-00381-6 PMID:33349658 PMCID:PMC8016738
  • Jiao N, Loomba R, Yang Z, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. 2021. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics doi:10.1152/physiolgenomics.00011.2021 PMID:34151600
  • Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. 2021. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70:1946-1953. doi:10.1136/gutjnl-2020-322976 PMID:33214165 PMCID:PMC8131405
  • Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wong VW, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. 2021. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161:1657-1669. doi:10.1053/j.gastro.2021.07.049 PMID:34602251 PMCID:PMC8819923
  • Loomba R. 2021. MRI-proton density fat fraction treatment response criteria in nonalcoholic steatohepatitis. Hepatology 73:881-883. doi:10.1002/hep.31624 PMID:33179266 PMCID:PMC8221026
  • Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. 2021. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 73:126-143. doi:10.1002/hep.31523 PMID:32794259 PMCID:PMC7898628
  • Loomba R, Ratziu V, Harrison SA. 2021. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162(3):doi:10.1053/j.gastro.2021.10.051 PMID:34822801
  • Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. 2021. Systematic review and network meta-analysis: Comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 54(7):880-889. doi:10.1111/apt.16583 PMID:34435378
  • Park JG, Jung J, Loomba R. 2021. Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Author's reply. Aliment Pharmacol Ther 52(2):PMID:34170539
  • Park JG, Jung J, Verma KK, Kang M, Madamba E, Lopez S, Yonan AQ, Liu A, Bettencourt R, Sirlin C, Loomba R. 2021. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther doi:10.1111/apt.16324 PMID:33764550
  • Ruuskanen MO, Aberg F, Mannisto V, Havulinna AS, Meric G, Liu Y, Loomba R, Vazquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa VV, Jain M, Knight R, Lahti L, Niiranen TJ. 2021. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 13:1-22. doi:10.1080/19490976.2021.1888673 PMID:33651661 PMCID:PMC7928040
  • Sharpton SR, Schnabl B, Knight R, Loomba R. 2021. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab 33(1):21-32. doi:10.1016/j.cmet.2020.11.010 PMID:33296678 PMCID:PMC8414992
  • Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin C, Loomba R. 2021. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 19(11):2274-2283.e5. doi:10.1016/j.cgh.2020.08.061 PMID:32882428 PMCID:PMC7914285
  • Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. 2021. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology 75(3):doi:10.1002/hep.32145 PMID:34496054
  • Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, Toyoda H, Loomba R, Izumi N. 2021. Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of Hepatitis C virus. Hepatol Commun PMID:34676692
  • Tamaki N, Munaganuru N, Jung J, Valasek MA, Behling C, Loomba R, Yonan AQ, Bettencourt R, Ajmera VH. 2021. Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD. Clin Gastroenterol Hepatol 19(12):doi:10.1016/j.cgh.2020.11.005 PMID:33157318 PMCID:PMC8438785
  • Vilarinho S, Ajmera VH, Zheng M, Loomba R. 2021. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 74(4):doi:10.1002/hep.32047 PMID:34233030 PMCID:PMC8463418

2020

  • Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek MA, Behling C, Richards L, Sirlin C, Loomba R. 2020. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology 71(3):849-860. doi:10.1002/hep.30974 PMID:31556124 PMCID:PMC7828573
  • Balakrishnan M, Loomba R. 2020. The role of noninvasive tests for differentiating NASH from NAFL and diagnosing advanced fibrosis among patients with NAFLD. J Clin Gastroenterol 54(2):107-113. doi:10.1097/MCG.0000000000001284 PMID:31789757 PMCID:PMC7945957
  • Dufour J, Caussy C, Loomba R. 2020. Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges. Gut 69:1877-1884. doi:10.1136/gutjnl-2019-319104 PMID:32381514 PMCID:PMC7497577
  • Han A, O'Brien WD, Erdman JW, Byra M, Heba E, Andre MP, Loomba R, Sirlin C. 2020. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat with radiofrequency ultrasound data using one-dimensional convolutional neural networks. Radiology 295:342-350. doi:10.1148/radiol.2020191160 PMID:32096706 PMCID:PMC7193902
  • Han A, Zhang YN, Boehringer AS, Montes V, Andre MP, Erdman JW, Loomba R, Valasek MA, Sirlin C, O'Brien WD. 2020. Assessment of hepatic steatosis in nonalcoholic fatty liver disease by using quantitative US. Radiology 295:106-113. doi:10.1148/radiol.2020191152 PMID:32013792 PMCID:PMC7104700
  • Hydes TJ, Ravi S, Loomba R, Gray ME. 2020. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. Clin Mol Hepatol 26:doi:10.3350/cmh.2020.0067 PMID:32674529 PMCID:PMC7641567
  • Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Wisplinghoff H, Gao B, Kasper P, Roderburg C, Tacke F, Steffen H, Goeser T, Abraldes JG, Tu XM, Loomba R, Starkel P, Pride D, Fouts DE, Schnabl B. 2020. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology 159:1839-1852. doi:10.1053/j.gastro.2020.07.005 PMID:32652145
  • Long MT, Gandhi S, Loomba R. 2020. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 111s:154259. doi:10.1016/j.metabol.2020.154259 PMID:32387227 PMCID:PMC7529729
  • Loomba R, Lim JK, Patton H, El-Serag HB. 2020. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 158:1822-1830. doi:10.1053/j.gastro.2019.12.053 PMID:32006545 PMCID:PMC8012107
  • Mangla N, Ajmera VH, Caussy C, Sirlin C, Brouha SS, Bajwa-Dulai S, Madamba E, Bettencourt R, Richards L, Loomba R. 2020. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol Hepatol 18(3):744-746. doi:10.1016/j.cgh.2019.05.003 PMID:31100460 PMCID:PMC6984972
  • Mouzaki M, Loomba R. 2020. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 18:270-280. doi:10.1007/s11938-020-00290-2 PMID:33716495 PMCID:PMC7946055
  • Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba E, Bettencourt R, Richards L, Raffatellu M, Dorrestein PC, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin C, Knight R, Downes M, Evans RM, Loomba R. 2020. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab 32:doi:10.1016/j.cmet.2020.10.015 PMID:33147487 PMCID:PMC7891106 (accepted for publication)
  • Sriram K, Loomba R, Insel PA. 2020. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenge. Proc Natl Acad Sci U S A 117:29274-29282. doi:10.1073/pnas.2009875117 PMID:33203679 PMCID:PMC7703541
  • Stender S, Loomba R. 2020. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 71:777-779. doi:10.1002/hep.31113 PMID:31954067
  • Verna EC, Serper M, Chu J, Corey K, Fix OK, Hoyt K, Page KA, Loomba R, Li M, Everson GT, Fried MW, Garcia-Tsao G, Terrault N, Lok AS, Chung RT, Reddy KR. 2020. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology 72:1819-1837. doi:10.1002/hep.31491 PMID:32740969 PMCID:PMC7435542
  • Zhao P, Sun X, Chaggan C, Liao Z, Wong KI, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR. 2020. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367:doi:10.1126/science.aay0542 PMID:32029622 PMCID:PMC8012106 (accepted for publication)

2019

  • Castera L, Friedrich-Rust M, Loomba R. 2019. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 156(5):1264-1281. doi:10.1053/j.gastro.2018.12.036 PMID:30660725 PMCID:PMC7505052
  • Caussy C, Bhargava M, Villesen I, Gudmann N, Leeming D, Karsdal M, Faulkner C, Bao D, Liu A, Lo M, Bettencourt R, Bassirian S, Richards L, Brenner DA, Chen C, Sirlin C, Loomba R. 2019. Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. Hepatology 70(1):127-141. doi:10.1002/hep.30610 PMID:30859582 PMCID:PMC6984974
  • Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu Z, Downes M, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. 2019. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 10:1406. doi:10.1038/s41467-019-09455-9 PMID:30926798 PMCID:PMC6440960
  • Loomba R, Adams L. 2019. The 20 Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH. Hepatology 70(6):1885-1888. doi:10.1002/hep.30946 PMID:31520407 PMCID:PMC7504908
  • Mills P, Caussy C, Loomba R. 2019. Glyphosate Excretion is Associated with Steatohepatitis and Advanced Liver Fibrosis in Patients with Fatty Liver Disease. Clin Gastroenterol Hepatol 18(3):741-743. doi:10.1016/j.cgh.2019.03.045 PMID:30954713 PMCID:PMC6776714
  • Mouzaki M, Loomba R. 2019. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 12:1756284819858470. doi:10.1177/1756284819858470 PMID:31258623 PMCID:PMC6591661
  • Pai R, Kleiner D, Hart J, Adeyi O, Clouston A, Behling C, Jain D, Kakar S, Brahmania M, Burgart L, Batts K, Valasek MA, Torbenson M, Guindi M, Wang H, Ajmera VH, Adams L, Parker CE, Feagan B, Loomba R, Jairath V. 2019. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 50(10):1100-1111. doi:10.1111/apt.15503 PMID:31583739 PMCID:PMC6817398
  • Wang L, Mazagova M, Pan C, Yang S, Brandl KL, Liu J, Reilly SM, Wang Y, Miao Z, Loomba R, Lu N, Guo Q, Liu J, Yu RT, Downes M, Evans RM, Brenner DA, Saltiel AR, Beutler B, Schnabl B. 2019. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proc Natl Acad Sci U S A 116:15184-15193. doi:10.1073/pnas.1904360116 PMID:31289229 PMCID:PMC6660779

2018

  • Ajmera VH, Park CC, Caussy C, Singh S, Hernandez C, Bettencourt R, Hooker J, Sy E, Behling C, Xu R, Middleton MS, Valasek MA, Faulkner C, Rizo E, Richards L, Sirlin CB, Loomba R. 2018. Magnetic Resonance Imaging Proton Density Fat Fraction Associates with Progression of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology 155(2):307-310. doi:10.1053/j.gastro.2018.04.014 PMID:29660324 PMCID:PMC6090543
  • Brouha SS, Nguyen P, Bettencourt R, Sirlin CB, Loomba R. 2018. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: a prospective study. Eur Radiol 28:1345-1355. doi:10.1007/s00330-017-5075-6 PMID:29058029 PMCID:PMC6310479
  • Caussy C, Hsu CL, Lo M, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen C, Loomba R. 2018. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology 68(3):918-932. doi:10.1002/hep.29892 PMID:29572891 PMCID:PMC6151296
  • Desai AP, Mohan P, Roubal AM, Bettencourt R, Loomba R. 2018. Geographic Variability in liver disease-related mortality rates in the United States. Am J Med 131:728-734. doi:10.1016/j.amjmed.2018.01.047 PMID:29496501 PMCID:PMC6090542
  • Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Starkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. 2018. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology doi:10.1002/hep.29676 PMID:29159825 PMCID:PMC5962369
  • Kim J, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, Kaufman RJ, Saltiel AR, Karin M. 2018. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell 175(1):133-145. doi:10.1016/j.cell.2018.08.020 PMID:30220454 PMCID:PMC6159928
  • Tapper EB, Loomba R. 2018. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. Hepatology 67:1657-1659. doi:10.1002/hep.29722 PMID:29222913 PMCID:PMC5906195
  • Tapper EB, Loomba R. 2018. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol 15:274-282. doi:10.1038/nrgastro.2018.10 PMID:29463906
  • Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. 2018. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15:397-411. doi:10.1038/s41575-018-0011-z PMID:29748586 PMCID:PMC6319369

2017

  • Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen C, Al Ikhwan M, Bassirian S, Cepin S, Gonzalez MP, Mendler M, Kono Y, Vodkin I, Mekeel K, Haldorson J, Hemming A, Andrews B, Salotti J, Richards L, Brenner DA, Sirlin CB, Loomba R. 2017. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 127(7):2697–2704. doi:10.1172/JCI93465 PMID:28628033 PMCID:PMC5490764
  • Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. 2017. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557-1565. doi:10.1002/hep.29085 PMID:28130788 PMCID:PMC5397356
  • Kim RG, Loomba R, Prokop LJ, Singh S. 2017. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 15(10):1521-1530. doi:10.1016/j.cgh.2017.04.039 PMID:28479502 PMCID:PMC5605397
  • Lin SC, Heba E, Bettencourt R, Lin GY, Valasek MA, Lunde O, Hamilton G, Sirlin CB, Loomba R. 2017. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging. Aliment Pharmacol Ther 45(6):844-854. doi:10.1111/apt.13951 PMID:28116801 PMCID:PMC5346270
  • Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen C, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. 2017. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25(5):1054-1062.e5. doi:10.1016/j.cmet.2017.04.001 PMID:28467925 PMCID:PMC550273
  • Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Valasek MA, Rizo E, Brenner DA, Sirlin CB, Loomba R. 2017. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152(3):598-607.e2. doi:10.1053/j.gastro.2016.10.026 PMID:27911262 PMCID:PMC5285304
  • Reinders ME, Wardi G, Bettencourt R, Bouland D, Bazick J, Mendler M, Vodkin I, Kalmaz D, Savides T, Brenner DA, Sell RE, Loomba R. 2017. Increased risk of death, in the hospital and outside the intensive care unit, for patients with cirrhosis after cardiac arrest. Clin Gastroenterol Hepatol 15(11):1808-1810. doi:10.1016/j.cgh.2017.05.044 PMID:28602970 PMCID:PMC5723019
  • Shalapour S, Lin X, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner CW, Anstee QM, Karin M. 2017. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551(7680):340-345. doi:10.1038/nature24302 PMID:29144460 PMCID:PMC5884449

2016

  • Cui J, Chen C, Lo M, Schork N, Bettencourt R, Gonzalez MP, Bhatt A, Hooker J, Shaffer K, Nelson KE, Long MT, Brenner DA, Sirlin CB, Loomba R. 2016. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology 64(5):1547-1558. doi:10.1002/hep.28674 PMID:27315352 PMCID:PMC5090982

2015

2013

  • Yang L, Inokuchi-Shimizu S, Roh Y, Song J, Loomba R, Park E, Seki E. 2013. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology 144(5):1042-1054. doi:10.1053/j.gastro.2013.01.056 PMID:23391818 PMCID:PMC3752402
Back
to Top